IDiyas

For the Inventor, By the Inventor

Berlin, Germany

Karl-Heinz Thierauch

USPTO Granted Patents = 29 

 

Average Co-Inventor Count = 7.3

ph-index = 8

Forward Citations = 235(Granted Patents)


Company Filing History:

goldMedal13 out of 1,384 
 
Schering Aktiengesellschaft
 patents
silverMedal9 out of 192 
 
Bayer Schering Pharma Ag
 patents
bronzeMedal5 out of 3,923 
 
Novartis Ag
 patents
4. 2 out of 721 
 
Bayer Intellectual Property Gmbh
 patents
5. 1 out of 132 
 
Seattle Genetics, Inc.
 patents
6. 1 out of 1 
 
Schering Aktienegesellschaft
 patent
7. 1 out of 832,680 
Other
 patents
where one patent can have more than one assignee

Years Active: 1989-2015

Loading Chart...
Loading Chart...
29 patents (USPTO):Explore Patents
1. 8992932 - Binder-drug conjugates (ADCs) and use thereof (2015-03-31),
2. 8796253 - Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis (2014-08-05),
3. 8481539 - Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same (2013-07-09),
4. 8003655 - Substituted sulphoximines as TIE2 inhibitors and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same (2011-08-23),
5. 7906533 - Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors (2011-03-15),
6. 7902229 - Anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors (2011-03-08),
7. 7846928 - Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same (2010-12-07),
8. 7842809 - Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same (2010-11-30),
9. 7825114 - Substituted aminopyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same (2010-11-02),
10. 7795264 - Substituted arylpyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same (2010-09-14),
11. 7615565 - VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines (2009-11-10),
12. 7572794 - Anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors (2009-08-11),
13. 7479491 - Azanthranylalkyl and -cycloalkyl amides and their use as VEGF receptor inhibitors (2009-01-20),
14. 7429592 - Cyanoanthranilamide derivatives and the use thereof as medicaments (2008-09-30),
15. 7148357 - VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines (2006-12-12),

Title: Karl-Heinz Thierauch: Pioneering Innovations in Cancer Treatment

Introduction:

Karl-Heinz Thierauch, a renowned inventor based in Berlin, DE, has made a significant impact in the field of pharmaceuticals with a remarkable portfolio of 29 patents. His groundbreaking work primarily focuses on developing novel therapies for hyperproliferative and angiogenic diseases, particularly cancer.

Latest Patents:

Thierauch's recent patents include innovative binder-drug conjugates (ADCs) targeting the C4.4a protein, as well as heteroaryl substituted pyrazole derivatives effective in treating hyperproliferative disorders and angiogenesis-related diseases. These patents highlight his dedication to advancing treatment options for challenging medical conditions.

Career Highlights:

Throughout his career, Thierauch has held pivotal roles at esteemed pharmaceutical companies such as Schering Aktiengesellschaft and Bayer Schering Pharma AG. His expertise and innovative approach have significantly contributed to the development of cutting-edge pharmaceutical solutions.

Collaborations:

Thierauch has collaborated closely with notable industry experts, including Andreas Huth and Martin Haberey. Together, they have worked towards pushing the boundaries of pharmaceutical research and development, fostering a culture of innovation and excellence.

Conclusion:

Karl-Heinz Thierauch's relentless pursuit of innovation and his unwavering commitment to revolutionizing cancer treatment have positioned him as a pioneering figure in the pharmaceutical industry. His exceptional contributions continue to inspire and drive advancements in the field, offering hope and improved outcomes for patients worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…